Education
About Us
Working with TipRanks
Follow Us
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185)
:2185
2185 Stock Chart & Stats
HK$5.71
HK$0.03(1.94%)
At close: 4:00 PM EST
HK$5.71
HK$0.03(1.94%)
Day’s Range― - ―
52-Week RangeHK$1.65 - HK$10.77
Previous CloseN/A
Volume27.00K
Average Volume (3M)2.14M
Market Cap
HK$1.34B
Enterprise ValueHK$953.65M
Total Cash (Recent Filing)HK$312.87M
Total Debt (Recent Filing)HK$7.67M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Mar 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding235,703,410
10 Day Avg. Volume3,698,147
30 Day Avg. Volume2,141,365
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing LossesA consistent multi-year reduction in net losses signals improving cost control and R&D efficiency. This durable trend lowers the quantum of future funding needed, improves runway assumptions, and increases the probability management can reach clinical or commercial inflection points without immediate restructuring.
Low LeverageExtremely low debt provides structural financial flexibility for a capital-intensive biotech. With minimal interest burden and available balance-sheet capacity, the company can access equity financing, partnerships, or selective borrowing without immediate solvency pressure, preserving strategic optionality over months.
Improving Free Cash FlowA materially less-negative free cash flow trajectory indicates the business is beginning to convert spending into closer-to-sustainable cash outcomes. While still negative, an improving FCF trend reduces incremental funding needs and signals operational progress that can persist if cost discipline and program prioritization continue.
Bears Say
No RevenueAbsent revenue, the firm remains wholly pre-commercial and value depends on successful clinical outcomes or licensing deals. This structural lack of operating income maintains high execution risk, limited earnings visibility, and persistent dependency on external capital for extended periods.
Persistent Cash BurnChronic negative operating and free cash flow is a durable constraint: it forces recurring capital raises or dilutive partnerships, increases financing risk, and can divert management focus from long-term science to funding. Sustained burn without clear near-term revenue elevates dilution and execution risk.
Eroding Balance-sheet BaseDeclining assets and equity reflect cumulative losses eating shareholder capital, reducing the company's buffer to absorb setbacks. A shrinking balance sheet limits capacity for additional R&D investment or partnership leverage and increases reliance on external funding, weakening long-term competitive positioning.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H News
2185 FAQ
What was Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H lowest stock price was HK$1.65 and its highest was HK$10.77 in the past 12 months.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap is HK$1.34B.
When is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Mar 27, 2026 which is in 33 days.
How were Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H released its earnings results on Aug 26, 2025. The company reported -HK$0.12 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.12.
Is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H have?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H has 235,703,410 shares outstanding.
What happened to Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H reported an EPS of -HK$0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.967%.
Which hedge fund is a major shareholder of Shanghai Bio-Heart Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
387.50%
12-Months-Change
Fundamentals
Return on Equity
-14.87%
Trailing 12-Months
Asset Growth
14.26%
Trailing 12-Months
Company Description
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) Earnings & Revenues
Technical Analysis
Genor Biopharma Holdings Limited
―
TOT BIOPHARM International Co. Ltd.
―
Zhaoke Ophthalmology Ltd.
―
Immunotech Biopharm Ltd
―
Hightide Therapeutics Inc
―
Options Prices
Currently, No data available
---